SCHEDULE: Acumen Pharmaceuticals: Murray Jr. Discloses 5% Stake
Beneficial Ownership Filing
James B. Murray Jr. has reported beneficial ownership of 5.00% of Acumen Pharmaceuticals' common stock as of April 6, 2026, with a filing delay noted.
Summary
- James B. Murray Jr. has filed a Schedule 13G, reporting beneficial ownership of 3,611,360 shares of Acumen Pharmaceuticals, Inc. common stock, representing 5.00% of the outstanding shares as of April 6, 2026.
- This ownership includes 3,468,465 shares held by the James B. Murray, Jr. Revocable Trust and 142,895 shares held by Praxis Technologies LLC.
- Mr. Murray Jr. shares voting and dispositive power for the Praxis Technologies LLC shares with another manager.
- The filing indicates a delay in submission due to an inadvertent oversight.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral; it's a routine disclosure of ownership with a minor procedural delay, not indicative of company performance or strategic shifts.
Positives
- Reporting of beneficial ownership indicates an active stakeholder.
- The filing confirms a significant ownership stake of 5.00%.
Negatives
- The filing was submitted late due to an inadvertent oversight, which could raise minor concerns about internal controls or attention to detail.
Risks
- The filing does not explicitly mention any risks.
- Potential for increased scrutiny or questions from regulators regarding the late filing.
Future Outlook
No specific future outlook or guidance is provided in this Schedule 13G filing.
Management Comments
- The filing was submitted late due to an inadvertent oversight.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors and significant individual shareholders crossing the 5% ownership threshold. The late filing, while noted, is a procedural matter and does not inherently reflect on the company's operational performance.
Related Party Transactions
- Shares held by Praxis Technologies LLC, where James B. Murray Jr. is a manager and shares voting/dispositive power with another manager.
Stakeholder Impact
- Shareholders: The filing confirms a significant shareholder, which can influence market perception and potential activism.
- Management: The late filing may prompt internal review of compliance procedures.
Next Steps
- Continue to monitor future filings from James B. Murray Jr. and Praxis Technologies LLC for any changes in beneficial ownership.
- Monitor Acumen Pharmaceuticals' operational and financial performance as reported in subsequent SEC filings.
Key Dates
| Date | Description |
|---|---|
| 08/05/1991 | Date of Trust Agreement for the James B. Murray, Jr. Revocable Trust. |
| 03/24/2025 | Date as of which outstanding shares were disclosed in the prior year's 10-K. |
| 04/04/2025 | Date of Event Which Requires Filing of this Statement (as indicated on the cover page). |
| 04/04/2025 | Date as of which Mr. Murray beneficially owned 3,081,057 shares. |
| 03/27/2025 | Date Acumen Pharmaceuticals filed its Annual Report on Form 10-K for the period ending March 24, 2025. |
| 03/20/2026 | Date as of which outstanding shares were disclosed in the current year's 10-K. |
| 03/26/2026 | Date Acumen Pharmaceuticals filed its Annual Report on Form 10-K for the period ending March 20, 2026. |
| 04/06/2026 | Date as of which Mr. Murray beneficially owned 3,611,360 shares and the percentage of class ownership. |
| 04/07/2026 | Date of signature on the Schedule 13G filing. |
Keywords
Schedule 13G, Acumen Pharmaceuticals, James B. Murray Jr., Beneficial Ownership, Common Stock, SEC Filing, Praxis Technologies LLC, Revocable Trust
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.